Open-label Extension Study Of RN624

Pfizer

Status and phase: Completed; Phase 2

Conditions: Osteoarthritis; OA Knee Pain; Arthritis

Treatments: Drug: RN624 (PF-04383119)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00399490

RN624-CL007 (Other Identifier)

A4091009

Details and patient eligibility

About

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

Enrollment: 287 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled in Study RN624-CL006

Exclusion criteria

• The occurrence of any adverse event or condition during the controlled studies that, in the opinion of the Investigator, should exclude the subject from participating in the open-label extension
• Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

287 participants in 1 patient group

1

Experimental group

Treatment:

Drug: RN624 (PF-04383119)